HOUSTON, May 3 /PRNewswire/ -- IDev Technologies, Inc., an emerging
leader in the development and marketing of minimally invasive stent systems
for the treatment of peripheral vascular and non-vascular diseases, today
announces CE Mark approval for use of its stent in Europe.
Specifically, the CE Mark approval is in respect to the design,
development and manufacture of devices for removal of inadvertently
dislodged or misplaced objects from peripheral body vasculature, for
palliative treatment of Biliary strictures produced by malignant neoplasms
and for use in peripheral vasculature for failed PTA.
Thomas M. Tully, Chairman and CEO commented, "European approval for the
IDev Technologies, Inc. stent is the first critical step toward the
commercialization of this novel technology worldwide. The company is
initially preparing a limited distribution strategy to elite interventional
centers throughout Europe. These elite centers will be the first to offer
the innovative IDev Technologies, Inc. stent to over 2.5 million patients
who suffer from Critical Limb Ischemia in the developed world."
About IDev Technologies, Inc.
IDev Technologies, Inc. ("IDEV") is an Innovator and Developer of next
generation minimally invasive medical devices for the treatment of
peripheral vascular disease (PVD). PVD is currently treated by
interventional radiologists, vascular surgeons, and cardiologists. The
Company has recently received a CE Mark approval for use of the stent in
peripheral vascular and non-vascular applications and is preparing to
launch the product in Europe shortly. The IDev Technologies, Inc. stent is
a unique device that is a self- expandable nitinol stent with significant
radial force that is resistant to kinking, crushing and fracture potential.
Additionally, the unique delivery system allows for precise placement and
repositionability prior to deployment. These features represent a
significant advance over existing stent technologies for peripheral
SOURCE IDev Technologies, Inc.